The DOI matches its Crossref record; 17 of the 18 references it cites were found in a registry or an index.
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Abstract
Six healthy young male volunteers at a contract research organization were enrolled in the first phase 1 clinical trial of TGN1412, a novel superagonist anti-CD28 monoclonal antibody that directly stimulates T cells. Within 90 minutes after receiving a single intravenous dose of the drug, all six volunteers had a systemic inflammatory response characterized by a rapid induction of proinflammatory cytokines and accompanied by headache, myalgias, nausea, diarrhea, erythema, vasodilatation, and hypotension. Within 12 to 16 hours after infusion, they became critically ill, with pulmonary infiltrates and lung injury, renal failure, and disseminated intravascular coagulation. Severe and unexpected depletion of lymphocytes and monocytes occurred within 24 hours after infusion. All six patients were transferred to the care of the authors at an intensive care unit at a public hospital, where they received intensive cardiopulmonary support (including dialysis), high-dose methylprednisolone, and an anti-interleukin-2 receptor antagonist antibody. Prolonged cardiovascular shock and acute respiratory distress syndrome developed in two patients, who required intensive organ support for 8 and 16 days. Despite evidence of the multiple cytokine-release syndrome, all six patients survived. Documentation of the clinical course occurring over the 30 days after infusion offers insight into the systemic inflammatory response syndrome in the absence of contaminating pathogens, endotoxin, or underlying disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although the solid phase assay does not replicate in vivo presentation of TGN1412, which is not fully understood, it does induce substantial cytokine release equivalent to that reported in trial volunteers.”
From Severity of the TGN 1412 trial disaster cytokine storm correlated with IL‐2 release (2013) · cites this paper as [2]
Experimental — accuracy not yet measuredIn the citing paper
“In 2006, a life-threatening 'cytokine storm', not predicted by pre-clinical safety testing, rapidly occurred in all six healthy volunteers during the phase I clinical trial of the CD28 superagonist monoclonal antibody (mAb) TGN1412.”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“One of the most striking features of the TGN1412-mediated 'cytokine storm' observed in humans was substantial TNF-a release within the first hour of infusion followed by dramatic increases in IFN-g, IL-2, IL-6, IL-8 and IL-10 plasma concentrations within 4 h (Suntharalingam et al., 2006).”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“Concentrations of TNF-a measured by ELISA in culture supernatants collected 24 h after in vitro TGN1412 stimulation were also consistent with the peak concentrations reported in trial volunteers, with the considerable caveat that a comparison is being made between an in vitro system and an in vivo response.”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“However, despite similar in vitro expression kinetics for IFN-g following TGN1412 stimulation, the concentrations of IFN-g were far lower than TNF-a responses in vitro, and an order of magnitude lower than concentrations of IFN-g predicted from in vivo responses in trial participants (Suntharalingam et al., 2006).”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
35 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“10.1073/pnas.0501997102”
Cited work 10.1073/pnas.0501997102 · retracted 2009-07-09 · notice 10.1073/pnas.0906977106 · this paper published 2006-09-07
Citations
Cites
1 retracted
Gon, Y., Wood, M. R., Kiosses, W. B., Jo, E., Sanna, M., Chun, J. J. M., & Rosen, H. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501997102 · Cited by 128
RetractedBone, R. C., Balk, R. A., Cerra, F. B., Dellinger, R. P., Fein, A. M., Knaus, W. A., Schein, R. M. H., & Sibbald, W. J. (1992) · Chest · doi:10.1378/chest.101.6.1644 · Cited by 13,198
Bernard, G. R., Artigas, A., Brigham, K. L., Carlet, J., Falke, K., Hudson, L., Lamy, M., Legall, J. R., Morris, A., & Spragg, R. (1994) · American journal of respiratory and critical care medicine · doi:10.1164/ajrccm.149.3.7509706 · Cited by 6,746
Sepsis-Induced Apoptosis Causes Progressive Profound Depletion of B and CD4+ T Lymphocytes in Humans
Hotchkiss, R. S., Tinsley, K. W., Swanson, P. E., Schmieg, R. E., Hui, J. J., Chang, K. C., Osborne, D. F., Freeman, B. D., Cobb, J. P., Buchman, T. G., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.11.6952 · Cited by 934
Clinical risks for development of the acute respiratory distress syndrome.
Hudson, L. D., Milberg, J. A., Anardi, D., & Maunder, R. J. (1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.151.2.7842182 · Cited by 890
Brivet, F. G., Kleinknecht, D. J., Loirat, P., & Landais, P. J. M. (1996) · Critical Care Medicine · doi:10.1097/00003246-199602000-00003 · Cited by 879
Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., & Engert, A. (1999) · Blood · doi:10.1182/blood.v94.7.2217.419k02_2217_2224 · Cited by 657
Wing, M. G., Moreau, T., Greenwood, J., Smith, R. M., Hale, G., Isaacs, J., Waldmann, H., Lachmann, P. J., & Compston, A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119110 · Cited by 257
Beyersdorf, N., Gaupp, S., Balbach, K., Schmidt, J., Toyka, K. V., Lin, C.-H., Hanke, T., Hünig, T., Kerkau, T., & Gold, R. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051060 · Cited by 203
Cited by
Items 1,401–1,500 of 2,162
Antibody induced CD4 down-modulation of T cells is site-specifically mediated by CD64+ cells
Vogel, S., Grabski, E., Buschjäger, D., Klawonn, F., Döring, M., Wang, J., Fletcher, E. A. K., Bechmann, I., Witte, T., Ďurišin, M., et al. (2015) · Scientific Reports · doi:10.1038/srep18308 · Cited by 6
Liu, J., Guo, Y.-M., Onai, N., Ohyagi, H., Hirokawa, M., Takahashi, N., Tagawa, H., Ubukawa, K., Kobayashi, I., Tezuka, H., et al. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.12.018 · Cited by 5
The use of Human Tissues and Cells in Biomedical Research: The Unusual Suspects
Bennett, A. J. (2010) · Alternatives to Laboratory Animals · doi:10.1177/026119291003801s03 · Cited by 5
“Examples of crucial differences between humans and rodents range from the well-documented differential effects of peroxisome proliferator-activated receptor drugs, which are hepatocarcinogenic in rodents, but not in humans (12), to the catastrophic effects of TGN1412 — a drug that showed no discernable toxicity in rod…”
BackgroundTranslational immunotoxicology of immunomodulatory monoclonal antibodies
Brennan, F. R., & Kießling, A. (2016) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2016.08.002 · Cited by 5
“The life-threatening cytokine storm effects induced by TGN1412 [19] was a result of the unexpected”
BackgroundInfluentialSignificance of biologics in renal transplantation
Grgic, I., & Chandraker, A. K. (2017) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000496 · Cited by 6
Niehues, T. (2017) · Springer eBooks · doi:10.1007/978-3-319-68038-5_20 · Cited by 5
Impact of selective CD28 blockade on virus-specific immunity to a murine Epstein-Barr virus homolog
Crepeau, R. L., Elengickal, J. A., Muraglia, G. M. L., & Ford, M. L. (2019) · American Journal of Transplantation · doi:10.1111/ajt.15321 · Cited by 6
“Importantly, unlike the early CD28 agonist, TGN1412 [17], no agonist activity, as measured by T ‐ cell proliferation or cytokine release, was observed with lulizumab in a Phase II clinical trial of patients with systemic lupus erythematosus (SLE; ClinicalTrials.gov: NCT02265744), confirming the…”
BackgroundScott, M. D., Wang, D., Toyofuku, W. M., & Yang, X. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.86598 · Cited by 4
Mergenthaler, P., & Meisel, A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800687-0.00007-4 · Cited by 5
T-cell costimulation and other directed therapies
Choy, E. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-09138-1.00059-0 · Cited by 5
Animal models: value and translational potency
Mergenthaler, P., & Meisel, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820493-1.00028-3 · Cited by 5
Orrù, V., Steri, M., Cucca, F., & Fiorillo, E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.714461 · Cited by 5
Xu, Z., Zhou, X. K., Zhao, X., Lu, X., Tang, L. V., Shi, W., Yan, H., You, Y., & Wang, H. (2021) · Hematology · doi:10.1080/16078454.2021.1978752 · Cited by 7
Myelopoiesis of acute inflammation: lessons from TGN1412-induced cytokine storm
Panoskaltsis, N., McCarthy, N. E., & Knight, S. C. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02702-9 · Cited by 5
Self-citationMultiple-Sklerose-Update zur Pathophysiologie und neuen immuntherapeutischen Ansätzen
Kleinschnitz, C., Meuth, S. G., Kieseier, B. C., & Wiendl, H. (2007) · Der Nervenarzt · doi:10.1007/s00115-007-2261-9 · Cited by 6
Minimising risk in first-in-man trials
Hemelaar, J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60686-2 · Cited by 4
Dawn of the era of biologics in the treatment of the rheumatic diseases
Koopman, W. J. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23208 · Cited by 5
“Each of the six healthy adult male recipients of this biologic agent developed rapid onset multi-organ failure, necessitating hospitalization and intensive care (18).”
BackgroundIn Vitro Cytokine Release Assays: Reducing The Risk of Adverse Events in Man
Kirton, C. M., Gliddon, D., Bannish, G., Bembridge, G. P., & Coney, L. (2011) · Bioanalysis · doi:10.4155/bio.11.272 · Cited by 5
Shi, Q., Niu, Y., Cao, H., Zhou, X., Jiang, S., Liu, Z., & Fan, H. (2012) · Transplantation Proceedings · doi:10.1016/j.transproceed.2012.02.009 · Cited by 5
“5 mg was also effective in suppressing graft mononuclear infiltration, epithelial injury, submucous fibroproliferation, and luminal obliteration, but did not induce a systemic inflammatory response observed in a clinical phase I trial of trans-Golgi network 1412.(30) We hould keep in mind that there are differences be…”
BackgroundRegulatory Affairs Introduction
Green, J. D. (2009) · Toxicologic Pathology · doi:10.1177/0192623309332987 · Cited by 5
HIV Type-1 Latency: Targeted Induction of Proviral Reservoirs
Graci, J. D., Colacino, J. M., Peltz, S. W., Dougherty, J. P., & Gu, Z. (2009) · Antiviral chemistry & chemotherapy · doi:10.1177/095632020901900501 · Cited by 5
“Unfortunately global immune activation can result in a multitude of serious side effects [92,93], including induction of a ‘cytokine storm’ [94].”
BackgroundANCA-associated vasculitis: pathogenesis, novel markers of the disease and emerging therapies.
Dhaygude, A. P., Erdbrüegger, U., Haubitz, M., & Woywodt, A. (2009) · PubMed · Cited by 5
The Immune Synapse as a Novel Target for Therapy
Graca, L. (2007) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-8296-4 · Cited by 5
A new homeostatic model of the T cell systemPreprint
Szabados, T., & Bakács, T. (2010) · arXiv (Cornell University) · doi:10.48550/arxiv.1007.5035 · Cited by 5
Bispecific antibody combination therapies in diffuse large B‐cell lymphoma
Harrop, S., Minson, A. G., Steiner, T. M., Neeson, P. J., & Dickinson, M. J. (2025) · British Journal of Haematology · doi:10.1111/bjh.70228 · Cited by 6
Upadhyay, S., Nada, H., Cho, S., & Gabr, M. T. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118937 · Cited by 6
Analysis of Pro- and Anti-Inflammatory Gene Response Patterns in Patients Receiving Phage Therapy
Kasprzak, H., Przybylski, M., Fortuna, W., Letkiewicz, S., Rogóż, P., Bubak, B., Górski, A., & Międzybrodzki, R. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms27010172 · Cited by 6
“The history of biological therapies—most notably the cytokine-release reactions to Theralizumab—underscores the necessity of detailed immune characterization for novel agents [65].”
Evolution of bispecific and multispecific antibodies in cancer therapy
Fontana, E., Grochot, R. M., Kotecki, N., Doger, B., Nannini, S., & de Miguel, M. Á. F. (2026) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2026.101599 · Cited by 7
“17,18 As a result, other target combinations are being explored to improve safety, including TAA-restricted co-stimulatory agonists (e.g., TAA x CD28, TAA x 4-1BB), combinations of ICI and co-stimulatory agents (e.g., PD-L1 x 4-1BB), combinations of TAA x CD3 and TAA x CD28, and integrated…”
Regulation of immune checkpoint molecules in cancer immune evasion and therapy
Eris, C., Zu, C., Xiao, Y., Platten, M., & Sun, C. (2026) · Nature reviews. Cancer · doi:10.1038/s41568-026-00934-y · Cited by 10
“A prototypical example is TGN1412, a ‘superagonist’ anti-CD28 antibody that triggered a severe cytokine release syndrome in healthy volunteers by globally activating T cells irrespective of antigen engagement 275 .”
Liao, T.-Y., Liu, Y.-L., Chen, C.-Y., Wu, B.-T., Liu, E.-S., Hong, S.-T., Huang, B., Cheng, Y., Chen, M. J., Chuang, K., et al. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.141003 · Cited by 4
Heuberger, J. A. A. C., de Jongh, P., van Hoogdalem, E., Tamminga, W. J., de Graeff, P., & Groeneveld, G. J. (2025) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70090 · Cited by 4
CD28 Family and Chronic Rejection: “To Belatacept...and Beyond!”
da Silva, M. V., Machado, J. R., Rocha, L. P., Castellano, L. R. C., dos Reis, M. A., & Corrêa, R. R. M. (2012) · Journal of Transplantation · doi:10.1155/2012/203780 · Cited by 4
“Conversely, a clinical trial adopting this strategy showed that the administration of anti-CD28 in six volunteers initiated a systemic inflammatory response [139], probably due to a huge secretion of proinflammatory cytokines by stimulated T-cells [140].”
BackgroundTsuzuki, H., Nagatsuka, Y., Iwata, M., et al. (2021) · Heliyon · doi:10.1016/j.heliyon.2021.e08380 · Cited by 4
Communicating complex numeric information in clinical research
Bierer, B. E., & Kassis, S. B. (2023) · Frontiers in Communication · doi:10.3389/fcomm.2023.1096271 · Cited by 6
“A first-in-human and first-in class trial (Suntharalingam et al., 2006; Attarwala, 2010)—in which the investigational product represents a new class of compounds—is more uncertain than a first-inhuman trial of a second-generation product.”
BackgroundPhase I Studies: Innovations and Issues
Beninger, P. R. (2024) · Clinical Therapeutics · doi:10.1016/j.clinthera.2024.01.002 · Cited by 5
Rakké, Y. S., Buschow, S. I., IJzermans, J. N. M., & Sprengers, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1357333 · Cited by 4
“This was illustrated by a fi rst-in-human clinical trial of a CD28 agonistic antibody where all healthy volunteers developed life-threatening immune-related adverse events (irAE) as a direct result of a cytokine release syndrome (43).”
MethodAnyalebechi, J. C., Sun, Y., Davis, C., Wagener, M. E., Liang, Z., Burd, E. M., Coopersmith, C. M., & Ford, M. L. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1346097 · Cited by 4
Revolutionizing Cancer Treatment: Unveiling the Power of CAR T-cell Therapy
Barjasteh, A. H., Saebi, M., Mahmoudi, M., Kheder, R. K., Hashemy, S. I., Forouzanfar, F., & Esmaeili, S. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128336391241107112957 · Cited by 5
Regulatory Guidelines and their Application in the Nonclinical Evaluation of Biological Medicines
Todd, M. D., & Dempster, M. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-394810-6.00002-2 · Cited by 4
Trastuzumab-induced CCL20 and interleukin-8 mRNA in human whole blood ex vivo
Hasegawa, S., Kato, H., Yamaguchi, H., et al. (2009) · Investigational New Drugs · doi:10.1007/s10637-009-9223-y · Cited by 4
“Although antibody drugs are generally considered safe, humanized anti-CD28 monoclonal antibody (TGN1412) had an episode of unexpected life threatening multiple organ failure during phase I clinical trials [1].”
BackgroundEffector Cell Recruitment by Bispecific Antibodies
Kellner, C., Peipp, M., & Valerius, T. (2011) · Springer eBooks · doi:10.1007/978-3-642-20910-9_13 · Cited by 4
Humanized Mice as Preclinical Models in Transplantation
Safinia, N., Becker, P. D., Vaikunthanathan, T., Xiao, F., Lechler, R. I., & Lombardi, G. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-3139-2_11 · Cited by 4
Greenberg, H. E., van Iersel, M. T., Westrick, M. L., & Smith, W. B. (2017) · Therapeutic Innovation & Regulatory Science · doi:10.1177/2168479017706404 · Cited by 4
“The TSSC, from the time it was set up (January 25, 2016) to issue its report (April 18, 2016), worked according to three methods: (1) individual expert appraisal of the documents provided to each member; (2) two 1-day “open” meetings (February 15, 2016, and March 24, 2016) during which the expert appraisals were read;…”
BackgroundMethodInfluentialPsychiatric Drug Discovery and Development
Shahid, M., Neill, J. C., & Hutchison, J. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623465.004 · Cited by 5
Innate responses to gut microbiota; critical assessment of the necessary experimental controls
McCoy, K. D., & Ohland, C. (2020) · Current Opinion in Microbiology · doi:10.1016/j.mib.2020.07.008 · Cited by 5
Rituximab induced cytokine release syndrome in an MS patient: A case report
Etemadifar, M., Salari, M., Saeri, M., et al. (2021) · Clinical Case Reports · doi:10.1002/ccr3.4407 · Cited by 4
A review on the COVID-19: Facts and current situation
Tiwari, U., Bano, A., & Khan, M. K. A. (2021) · NeuroPharmac Journal · doi:10.37881/1.616 · Cited by 4
Highly sensitive in vitro cytokine release assay incorporating high-density preculture
Ito, S., Miwa, K., Hattori, C., Aida, T., Tsuchiya, Y., & Mori, K. (2021) · Journal of Immunotoxicology · doi:10.1080/1547691x.2021.1984617 · Cited by 6
“Cytokine release syndrome (CRS), which occurred in the Phase-I clinical trial of the anti-CD28 super-agonist (SA) monoclonal antibody (mAb) TGN1412, is one of the most serious adverse effects associated with parenteral administration of therapeutic mAb (Suntharalingam et al. 2006).”
BackgroundMadsen, N. H., Gad, M., & Larsen, J. (2022) · Journal of Immunological Methods · doi:10.1016/j.jim.2022.113231 · Cited by 4
Braun, T., & Schrader, A. (2023) · Cancers · doi:10.3390/cancers15092532 · Cited by 6
“The latter was evaluated in a Phase I clinical trial, resulting in severe clinical illness and the hospitalization of all six healthy volunteers due to a cytokine storm-induced systemic inflammatory response [5].”
BackgroundThe application of antibody-based agents in cancer therapy based on their mechanisms of action
Qian, K., Li, G., Zhang, S., Zou, Y., Ai, H., Zheng, X., Fu, W., Lei, C., & Hu, S. (2024) · Fundamental Research · doi:10.1016/j.fmre.2024.02.021 · Cited by 6
“Within 90 min after receiving a single intravenous dose of the drug, all six participants had a systemic inflammatory response syndrome, and unexpected depletion of lymphocytes and monocytes was observed within 24 h after infusion [49] .”
Who's Winning the IRB Wars? The Struggle for the Soul of Human Research
King, N. M. P. (2018) · Perspectives in biology and medicine · doi:10.1353/pbm.2018.0055 · Cited by 4
Small molecules—Giant leaps for immuno-oncology
Kötzner, L., Huck, B. R., Garg, S., & Urbahns, K. (2020) · Progress in medicinal chemistry · doi:10.1016/bs.pmch.2019.11.001 · Cited by 7
The Perfect Storm: A Rheumatologist's Point of View on COVID-19 Infection
Kobak, Ş. (2020) · Current Rheumatology Reviews · doi:10.2174/1573397116666201029155105 · Cited by 4
Nugent, P., Duncan, J. N., & Colagiovanni, D. B. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-387815-1.00012-5 · Cited by 4
Efficacy and safety of new medicines: a human focus
Coleman, R. A. (2010) · Cell and Tissue Banking · doi:10.1007/s10561-010-9200-x · Cited by 5
“And of course the R. A. Coleman (&) Safer Medicines Trust, PO Box 62720, London SW2 9FQ, UK e-mail: robt.coleman@btinternet.com notorious Te Genero drug, TGN1412, that caused such devastating effects in human volunteers in its first exposure to man at Northwick Park (Suntharalingam et al. 2006) was extremely well-tole…”
BackgroundInfluentialCellular immune response to an engineered cell-based tumor vaccine at the vaccination site
Zhou, Q., Johnson, B. D., & Orentas, R. J. (2007) · Cellular Immunology · doi:10.1016/j.cellimm.2007.04.004 · Cited by 4
Sedative effects of Mozartʼs music in the critically ill: Enjoy the hormonal symphony *
Paugam‐Burtz, C., & Mantz, J. (2007) · Critical Care Medicine · doi:10.1097/01.ccm.0000295271.66929.01 · Cited by 4
“Sepsis and acute respiratory distress syndrome represent such situations routinely encountered in ICU patients (7, 8).”
BackgroundHaanen, J. B. A. G., & Schumacher, T. N. (2007) · Nature Medicine · doi:10.1038/nm0307-248 · Cited by 4
Biosimilars versus generics: scientific basics and clinical implications
Sitte, H. H., & Freissmuth, M. (2013) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-013-0094-8 · Cited by 4
Pongratz, G., & Fleck, M. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802502161 · Cited by 4
“The worst example was the severe systemic inflammatory response syndrome that occurred in six volunteers following the administration of a stimulatory anti-CD28 antibody [154].”
BackgroundT-cell co-stimulatory blockade in kidney transplantation: back to the bench
Riella, L. V., & Sayegh, M. H. (2011) · Kidney International Supplements · doi:10.1038/kisup.2011.8 · Cited by 5
Zhang, L. A., Parker, R. S., Swigon, D., Banerjee, I., Bahrami, S., Redl, H., & Clermont, G. (2016) · Critical Care Medicine · doi:10.1097/ccm.0000000000001623 · Cited by 5
“Frustratingly, therapies that have shown promise in animal models have often failed in human trials because of a lack of efficacy or safety concerns (5, 6).”
BackgroundCytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Gordon, M. S. (2008) · Yearbook of Oncology · doi:10.1016/s1040-1741(08)79133-4 · Cited by 4
A Human Approach to Drug Development: Opportunities and Limitations
Coleman, R. A. (2010) · Alternatives to Laboratory Animals · doi:10.1177/026119291003801s06 · Cited by 4
PROTEIN THERAPEUTICS AND THEIR IMMUNOGENICITY
Thorpe, R., & Wadhwa, M. (2006) · Cited by 4
Preclinical Development of Monoclonal Antibodies
Meyer-Tamaki, K. B. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-387815-1.00021-6 · Cited by 4
Akute Überempfindlichkeitsreaktionen auf monoklonale Antikörper zur zielgerichteten Therapie
Sachs, B., & Merk, H. F. (2018) · Der Hautarzt · doi:10.1007/s00105-018-4142-5 · Cited by 4
Freiberger, S. N., Leuthard, D., Duda, A., Contassot, E., Thallmair, M., Kündig, T. M., & Johansen, P. (2018) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2018.01.042 · Cited by 5
Graft-Versus-Host Disease and Graft-Versus-Leukemia Responses
Reddy, P. R., & Ferrara, J. L. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35762-3.00108-6 · Cited by 5
Development of a human leukocyte antigen-based HIV vaccine
Wang, Y. (2018) · F1000Research · doi:10.12688/f1000research.13759.1 · Cited by 4
Zhang, E., Hou, Z., Shao, T., et al. (2017) · PubMed · Cited by 4
Visich, J. E., & Ponce, R. A. (2010) · Wiley eBooks · doi:10.1002/9780470571224.pse199 · Cited by 4
Bridging Immunotoxicology to Clinical Drug Development
Gourley, I. S., & Descotes, J. (2008) · doi:10.1002/9780470386385.ch26 · Cited by 4
Molecular Mediators: Cytokines
Cavaillon, J. (2015) · Wiley-VCH eBooks · doi:10.1002/3527600906.mcb.200400134.pub2 · Cited by 4
Human Volunteer Studies ??? Safety Considerations in an Era of Highly Active Biological Agents
Snell, N. J. C. (2006) · International Journal of Pharmaceutical Medicine · doi:10.2165/00124363-200620050-00002 · Cited by 4
“All were eventually discharged home.[12] So what was the agent that caused these devastating symptoms? TGN 1412 is a fully humanised monoclonal antibody to CD28, a co-stimulatory T-cell receptor.”
BackgroundInfluentialFrom mice to men: the challenges of developing tolerance-inducing biological drugs for the clinic
Ng, W., & Isaacs, J. D. (2007) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-8296-4_12 · Cited by 4
“When administered to healthy human volunteers, however, all six subjects developed multi-organ failure within 24 h. This was due to rapid release of pro-inflammatory cytokines through non-selective activation of T cells [ 38 ].”
BackgroundBREATHNACH, S. M., Smith, C. H., Chalmers, R. J. G., & Hay, R. J. (2010) · Wiley eBooks · doi:10.1002/9781444317633.ch74 · Cited by 8
Smith, C. H. (2016) · Wiley eBooks · doi:10.1002/9781118441213.rtd0014 · Cited by 4
Mazein, A., Lopata, O., Reiche, K., Sewald, K., Alb, M., Sakellariou, C. A., Gogesch, P., Morgan, H., Neuhaus, V., Pham, N.-N., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1601670 · Cited by 10
Bioengineered intestinal models: structural precision drives functional and microbial fidelity
Gao, Z., Du, H., Yu, S., Li, Q., Li, Y., Yin, J., Yang, H., Wang, Y., Zhou, H., & Shen, L. (2025) · Bio-Design and Manufacturing · doi:10.1631/bdm.2500353 · Cited by 3
Perspective of using in vitro models to understand immunotherapy-induced cytokine release syndrome
Perkins, E., Cooper, C., Lund, E., Alb, M., Morgan, H., Fogal, B., Hewitt, P. G., Mazein, A., Ostaszewski, M., & Sewald, K. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1732193 · Cited by 4
“Several high-pro fi le incidences of CRS have been reported in response to immunotherapies, most notable during the 2006 clinical trial of the CD28 superagonist TGN1412 monoclonal antibody (mAb) (3).”
Ponce, R. A. (2011) · Journal of Immunotoxicology · doi:10.3109/1547691x.2011.603390 · Cited by 3
“One need look no further than the well-publicized toxicity of TGN-1412 after a single dose in healthy volunteers to be reminded of the risks associated with attempting T-cell modulation (Suntharalingam et al., 2006).”
BackgroundTee, Y. C., Blake, S. J., & Lynn, D. J. (2021) · FASEB BioAdvances · doi:10.1096/fba.2021-00039 · Cited by 3
“However, despite numerous examples of IAAs inducing a beneficial anti-tumor effect in both clinical and pre-clinical settings (8, 9), the development of IAAs has been hampered by their propensity to induce high-grade and sometimes fatal immune related adverse events (irAEs).”
BackgroundWang, Z., Hu, N., Wang, H., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114618 · Cited by 3
Giving T-cell bispecifics a helping hand
Kobold, S. (2024) · Blood · doi:10.1182/blood.2024024346 · Cited by 3
Naser‐Tavakolian, A., Heard, J. R., & Ahdoot, M. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-90186-4.00001-8 · Cited by 3
Targeting T-Cell Costimulation to the Surface of Tumor Cells
Eguren‐Santamaría, I., Sanmamed, M. F., Molero-Glez, P., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-3003 · Cited by 3
Li, D., You, B., Guo, K., Zhou, W., Li, Y., Wang, C., Chen, X., Wang, Z., Zhang, J., & Si, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020678 · Cited by 3
Kameda, H., Maezawa, R., Minegishi, Y., Imaizumi, C., & Ogura, T. (2025) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.70202 · Cited by 3
Checkpoint Blockade Efficacy in Uveal Melanoma Is Linked to Tumor Immunity, CD28, and CCL8
Koch, E. A. T., Liguori, R., Castro, A. A., Schliep, S., Petzold, A., Wessely, A., Fröhlich, W., Ferrazzi, F., Vera, J., Eckstein, M., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26209964 · Cited by 5
“Notably, an anti-CD28 antibody (TGN1412) triggered a severe cytokine storm, resulting in life-threatening complications, 90 min after administration in a phase I trial [31].”
Safety Challenges Facing Next Generation Vaccines and the Role for Biomarkers
Ahmed, S., Oviedo‐Orta, E., & Ulmer, J. B. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5380-2_17 · Cited by 4
Using gene therapy to manipulate the immune system in the fight against B-cell leukemias
Bouhassira, D. C. G., Thompson, J. J., & Davila, M. L. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1014792 · Cited by 3
“It is likely that the T cells are at the center of CRS, considering similar toxicities are seen in patients treated with an anti-CD28 antibody or blinatumomab, a CD19/CD3 bispecific T-cell engaging antibody [52,53].”
BackgroundChanneling postmarketing patient data into pharmaceutical regulatory systems
Barbosa, M. D. F. S., & Smith, D. D. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.07.011 · Cited by 3
Johnson, V. J., Germolec, D. R., Luebke, R. W., et al. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.99181-5 · Cited by 3
CD28 Superagonistic Activation of T Cells Induces a Tumor Cell-Like Metabolic Program
Thaventhiran, T., Wong, W., Alghanem, A. F., Alhumeed, N., Aljasir, M. A., Ramsey, S. J., Sethu, S., Yeang, H. X. A., Chadwick, A. E., Cross, M. J., et al. (2019) · Monoclonal Antibodies in Immunodiagnosis and Immunotherapy · doi:10.1089/mab.2018.0042 · Cited by 3
“TGN1412, a CD28SA, triggered an excessive and adverse cytokine release (cytokine storm) when administered to volunteers in a human Phase 1 clinical trial.((2)) We and others have shown that CD28SA induces exaggerated activation, polyclonal expansion, and migration of CD4 effector memory T cells (TEMs).”
BackgroundRegulating innovation in the early development of cell therapies
Exley, A., & McBlane, J. W. (2020) · Immunotherapy Advances · doi:10.1093/immadv/ltaa011 · Cited by 4
“Notable toxicity first identified in clinical testing is not a new phenomenon, occurring repeatedly throughout the history of drug development [124, 125, 126].”
BackgroundPredicting Multi-Epitope Peptide Cancer Vaccine from Novel TAA Topo48
Setiawan, T., & Rizarullah, R. (2021) · Journal of Science and Applicative Technology · doi:10.35472/jsat.v5i1.349 · Cited by 3
“Another peptide vaccine derived from mouse and monkey model cause antibody-induce cytokine storm in healthy donor in clinical trial [12].”
BackgroundChimeric antigen receptor T-cell therapy: An emergency medicine focused review
Long, B., Yoo, M. J., Brady, W. J., Holian, A., Sudhir, A., & Gottlieb, M. A. (2021) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2021.08.042 · Cited by 4
Rojas, J. M., Mancho, C., Louloudes-Lázaro, A., Rodríguez-Martín, D., Avia, M., Moreno, S., Sevilla, N., & Martín, V. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.1010873 · Cited by 3
Metadata
- Authors
- Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N.
- Affiliations
- Hammersmith Hospital (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-09-07
- Volume
- 355
- Issue
- 10
- Pages
- 1018-1028
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2141989396
- Cited by
- 2,164
- References
- 18
- Citations by year
- 2026: 57 · 2025: 73 · 2024: 95 · 2023: 79 · 2022: 79 · 2021: 120 · 2020: 141 · 2019: 94 · 2018: 102 · 2017: 97 · 2016: 117 · 2015: 122 · 2014: 118 · 2013: 120 · 2012: 114
- FWCI
- 80.54
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Keywords
- cytokine release syndrome, TGN1412, anti-CD28 monoclonal antibody, systemic inflammatory response syndrome, inflammatory cytokines, acute respiratory distress syndrome, disseminated intravascular coagulation, renal failure, drug-induced immunotoxicity
- MeSH terms
- Adult, Antibodies, Monoclonal, C-Reactive Protein, Critical Care, Double-Blind Method, Hemodynamics, Humans, Hypotension, Infusions, Intravenous, Leukopenia, Male, Multiple Organ Failure, Thrombocytopenia, Cytokines, CD28 Antigens, Disease Progression, APACHE, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.